Table 2 Comparison of S-antibody titers between two consecutive visits in group I participants*.

From: Antibody longevity and waning following COVID-19 vaccination in a 1-year longitudinal cohort in Bangladesh

 

Pfizer

Moderna

AstraZeneca

Sinopharm

Between visit 1 & 2

    
 

n = 84

n = 70

n = 118

n = 63

Visit 1

14,223.3 ± 12.0

17,060.8 ± 20.4

2576.3 ± 31.5

1399.6 ± 13.5

Visit 2

6194.4 ± 22.0

6966.3 ± 12.5

963.8 ± 14.30

707.9 ± 14.20

P value

 < 0.001

 < 0.001

 < 0.001

 < 0.001

Between visit 2 & 3

    
 

n = 27

n = 19

n = 99

n = 8

Visit 2

7430.2 ± 13.8

8629.8 ± 16.2

1339.7 ± 12.0

2779.7 ± 20.4

Visit 3

4592.0 ± 15.1

5358.0 ± 14.1

743.0 ± 14.8

1717.9 ± 15.5

P value

 < 0.001

 < 0.001

 < 0.001

 < 0.001

Between visit 3 & 4

    
 

n = 10

n = 8

 

n = 13

Visit 3

6531 ± 16.80

10,280 ± 19.2

–

2153 ± 30.4

Visit 4

3617 ± 20.2

7032 ± 19.7

–

794.0 ± 26.3

P value

 < 0.001

 < 0.001

 

 < 0.001

  1. Data are presented as GM ± SD. Multivariate regression model was used to calculate the estimated mean and the regression model was adjusted by age, sex, household income, occupation, and BMI. *Group I consists of individuals who remained uninfected with SARS-CoV-2 (tested negative by RT-PCR, did not exhibit COVID-like symptoms or negative for N-antibodies) and did not receive the 3rd dose of vaccine during the one-year study period. BMI: Body mass index; SARS-CoV-2: Severe acute respiratory coronavirus-2; GM: Geometric mean; SD: Standard deviation; RT-PCR: Reverse transcription polymerase chain reaction.
Back to article page